Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-11-21
DOI
https://doi.org/10.1080/14796694.2025.2586004
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study

Myung‐Ju Ahn, Jacob M. Sands
Future Oncology
Lung Cancer Treatments and Mutations
article

Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study

Myung‐Ju Ahn, Jacob M. Sands
article en

Abstract

No abstract available for this paper.
Future OncologyVol. 22(3)
Samsung Medical Center (KR), Dana-Farber Cancer Institute (US), Sungkyunkwan University (KR)
Openalex Percentile: Top 49%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study — Myung‐Ju Ahn, Jacob M. Sands · Future Oncology (2025) | TGRS Research Map | TGRS